Article By:
Benzinga
Wednesday, June 17, 2020 10:37 AM EDT
Shares of Chembio Diagnostics Inc., which rallied nicely following the launch of its rapid DPP COVID-19 serological point-of-care test for the detection of IgM and IgG antibodies in late March, are pulling back sharply Wednesday.
In this article: CEMI
The Bullish Trend Continues - Sunday, Nov. 7
If someone is going to pay $700/pill for Pfizer's Covid Anti-Viral pill they'll want to be certain that they have Covid and not the flu. Chembio $CEMI has the dual Covid/flu test. Buy a few shares before the next p.r. doubles/triples the share price.
Bullish Outlook For Gold & Gold Stocks In 2022
"Better then gold." $CEMI. Chembio Diagnostics Substantially undervalued.
F.D.A. approval on its Covid/Flu test could happen at any time which will double/triple the share price. Last time it received approval on one of its tests, it traded over 600,000,000 shares in two days and hit $7.12 because the shorts had oversold it. Potential takeover target at $15+. Buy a few shares on before the next p.r.
Markets Down - Where To Invest Now
You are lucky to have bought $CEMI so early. Since I bought it, it's been down. Any idea why it has dropped so much from its recent high?